SEEGENE, INC. Logo

SEEGENE, INC.

Develops multiplex qPCR diagnostic assays and automated systems for labs and healthcare worldwide.

096530 | KO

Overview

Corporate Details

ISIN(s):
KR7096530001
LEI:
Country:
South Korea
Address:
서울특별시 송파구 오금로 91(방이동) 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seegene, Inc. is a global molecular diagnostics company specializing in the development and manufacturing of in vitro diagnostic (IVD) products. The company focuses on syndromic quantitative PCR (qPCR) technologies, offering multiplex assays that can simultaneously detect multiple pathogens from a single sample. Its product portfolio includes automated systems like STARlet-AIOS™ and solutions for respiratory infections, sexually transmitted infections (STIs), and HPV screening. Through strategic collaborations with partners such as Microsoft and a technology-sharing initiative called OneSystem™, Seegene aims to standardize and increase the accessibility of molecular diagnostics for healthcare providers and research laboratories worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 3.1 MB
2025-08-08 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-08-06 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-08-06 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-08-06 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.3 KB
2025-08-01 00:00
Report Publication Announcement
결산실적공시예고
Korean 4.0 KB
2025-06-11 00:00
Transaction in Own Shares
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 79.7 KB
2025-06-09 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 17.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.1 MB
2025-05-09 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 16.7 KB
2025-05-07 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정 (분기배당)
Korean 8.4 KB
2025-05-07 00:00
Notice of Dividend Amount
중간(분기)배당을위한주주명부폐쇄(기준일)결정
Korean 5.3 KB
2025-05-07 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 31.4 KB
2025-05-02 00:00
Report Publication Announcement
결산실적공시예고
Korean 4.0 KB

Automate Your Workflow. Get a real-time feed of all SEEGENE, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEEGENE, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEEGENE, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.